Advertisement
Clinical Trials
Subscribe to Clinical Trials
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Nine-Valent HPV Vaccine May Prevent Nearly 90% of Cervical Cancers

October 1, 2014 3:59 pm | News | Comments

Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to prevent more cervical cancers than current vaccines, according to new research. Read more...

Portola Pharmaceuticals Announces Phase 3 ANNEXA-A Data

October 1, 2014 3:45 pm | News | Comments

Portola Pharmaceuticals announced that its first Phase 3 study of andexanet alfa, a potential universal Factor Xa inhibitor antidote and U.S. Food and Drug Administration-designated breakthrough therapy, met its primary and secondary endpoints with high statistical significance. Read more...

Immunovaccine Announces Plans for Phase 2 Clinical Trial of DPX-Survivac

October 1, 2014 11:14 am | News | Comments

Immunovaccine Inc. (“Immunovaccine” or “IMV”), a clinical stage vaccine and immunotherapy company, provided a clinical development program update for DPX-Survivac, the company’s lead cancer vaccine candidate. Read more...

Advertisement

Targeted Treatment Could Halt Womb Cancer Growth

October 1, 2014 10:06 am | News | Comments

A drug which targets a key gene fault could halt an aggressive womb cancer and shrink tumours, according to research published in the British Journal of Cancer. Read more...

Sanofi, Regeneron Announce Positive Dupilumab Results

September 30, 2014 11:00 am | News | Comments

Regeneron Pharmaceuticals and Sanofi announced that a Phase 2a study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids. Read more...

Pfizer, Kyowa Hakko Kirin Partner on Immuno-Oncology Combo Study

September 30, 2014 10:49 am | News | Comments

Pfizer Inc. and Kyowa Hakko Kirin announced that they've entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s PF-05082566 with Kyowa Hakko Kirin’s anti-CCR4 antibody mogamulizumab. Read more...         

Takeda, Seattle Genetics Receive Positive Data from Lymphoma Trial

September 30, 2014 10:02 am | News | Comments

Seattle Genetics and Takeda Pharmaceutical Co. Ltd. announced that patients with Hodgkin lymphoma (HL) who received Adcetris (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplantation (ASCT) lived significantly longer without disease progression compared to patients who received placebo. Read more...

Array's Melanoma Drug Promising in Phase 2

September 29, 2014 3:46 pm | News | Comments

Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain. Invented by Array BioPharma Inc. and licensed to Novartis in 2010, binimetinib is a small molecule selective inhibitor of the kinases MEK1 and MEK2. Read more...

Advertisement

Tonix Fibromyalgia Pain Drug Misses Endpoint in Phase 2b

September 29, 2014 3:28 pm | News | Comments

Tonix Pharmaceuticals announced results of the Phase 2b BESTFIT study of TNX-102 SL as a chronic bedtime treatment for fibromyalgia. The study did not achieve statistical significance in the primary efficacy endpoint of change in average daily pain score at week 12. Read more...

Combo Treatment Ups PFS in Advanced Melanoma Patients

September 29, 2014 3:07 pm | News | Comments

Shares of Exelixis jumped Monday before markets opened and after the drugmaker said its treatment for a deadly form of skin cancer fared better than another drug in a late-stage clinical study. Read more...

Bristol-Myers Squibb Gets Positive Results for Nivoluma

September 29, 2014 2:58 pm | News | Comments

Bristol-Myers Squibb Co. announced positive results from CheckMate-037, a Phase 3 randomized, controlled open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma. Read more...

Cancer Research UK Increases Drug Development Investment

September 29, 2014 10:21 am | News | Comments

Cancer Research UK is to increase investment by nearly 50% over the next five years in its Drug Development Office, which is also changing its name to the Center for Drug Development (CDD). Read more...              

Genentech’s Perjeta Regimen Extended Lives

September 29, 2014 9:59 am | News | Comments

Genentech announced final survival results from the Phase 3 Cleopatra study, which showed that adding Perjeta to Herceptin and docetaxel chemotherapy extended the lives of people with previously untreated HER2-positive metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy. Read more...

Advertisement

MicroBiome Therapeutics' Drug May Limit Metformin Side Effects

September 26, 2014 3:47 pm | News | Comments

MicroBiome Therapeutics reported positive topline results from a proof-of-concept study testing whether its investigational drug, NM 505, can improve the tolerability of metformin, the first-line therapy for Type 2 diabetes worldwide. Read more...

Bausch + Lomb Receives Successful Results from Phase 3 Study

September 26, 2014 10:59 am | News | Comments

Bausch + Lomb announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3 study. Read more...

Gilead Gets Positive Opinion for HCV Tablet

September 26, 2014 10:48 am | News | Comments

Gilead Sciences Inc. announced that the CHMP, the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company's Marketing Authorization Application (MAA) for Harvoni, an investigational once-daily tablet combining the NS5A inhibitor (LDV) 90 mg and the nucleotide analog polymerase inhibitor (SOF) 400 mg for the treatment of HCV infection in adults. Read more...

MabVax Neuroblastoma Vaccine Gets Orphan Drug Designation

September 25, 2014 2:51 pm | News | Comments

MabVax Therapeutics Holdings Inc. announced that the FDA has granted orphan drug designation to the company's vaccine intended for the treatment of the childhood cancer neuroblastoma. Read more...               

Boehringer Ingelheim Announces FDA Approval of COPD Drug

September 25, 2014 1:31 pm | News | Comments

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the FDA approved Spiriva Respimat (tiotropium bromide) inhalation spray for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). Read more...

Novartis Psoriatic Arthritis Drug Hits Endpoints in Two Phase 3 Trials

September 25, 2014 10:06 am | News | Comments

Novartis announced that two pivotal Phase 3 studies (FUTURE 1 and FUTURE 2) of AIN457 (secukinumab) in psoriatic arthritis (PsA) met primary and key secondary endpoints. Read more...

Gilead's Investigational HIV Drug Meets Trial Goals

September 24, 2014 3:17 pm | News | Comments

Gilead Sciences Inc. announced that two Phase 3 clinical trials evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide for the treatment of HIV-1 infection in treatment-naïve adults met their primary objectives. Read more...

Inovio Pharma Plans Humans Trials of Ebola Vaccine

September 24, 2014 2:45 pm | News | Comments

Inovio Pharmaceuticals plans to initiate human testing of a DNA-based vaccine for the Ebola virus in the first half of 2015. Read more...                                

New Awards Apply Sex, Gender Lens to NIH-Funded Research

September 23, 2014 10:57 am | News | Comments

The NIH has invested $10.1 million in supplemental funding to bolster the research of 82 grantees to explore the effects of sex in preclinical and clinical studies. Read more...                     

Ebola Drug Trials to be Fast-Tracked in West Africa

September 23, 2014 10:48 am | News | Comments

Potential new treatments for Ebola are to be tested in West Africa for the first time as part of an international initiative to fast-track trials of the most promising drugs against the disease that has already led to over 2,600 deaths. Read more...

Tekmira’s Ebola Drug Gets Regulatory Framework

September 22, 2014 2:56 pm | News | Comments

Tekmira Pharmaceuticals Corp. announced that the FDA has authorized Tekmira to provide TKM-Ebola for treatment under expanded access protocols to subjects with confirmed or suspected Ebola virus infections. Read more...          

Lilly's Combo Treatment Improves OS in Gastric Cancer Patients

September 18, 2014 3:58 pm | News | Comments

Eli Lilly and Co. announced that results of the global Phase 3 trial of ramucirumab (Cyramza) in combination with paclitaxel in patients with advanced gastric (stomach) cancer or gastroesophageal junction (GEJ) adenocarcinoma were published in a sholarly journal. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading